Sun Pharmaceutical Industries

524715 · BSE · INR

₹1,810.00

Close · October 1, 2026

At a glance

Revenue growth: +11.19%; FY to Mar 2026 vs FY to Mar 2025
Net income growth: +5.04%; FY to Mar 2026 vs FY to Mar 2025
Net margin: 19.6%; FY to Mar 2025: 20.8%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

Income statement · Annual
Item	FY to Mar 2026	FY to Mar 2025	FY to Mar 2024	FY to Mar 2023	FY to Mar 2022	FY to Mar 2021	FY to Mar 2020	FY to Mar 2019	FY to Mar 2018	FY to Mar 2017
Total revenue	584,620	525,784	484,969	438,857	386,545	334,981	328,375	290,659	264,155	313,081
Cost of revenue	124,786	115,585	114,422	113,187	108,761	92,185	96,796	83,839	77,771	82,701
Gross profit	459,834	410,200	370,547	325,670	277,784	242,796	231,579	206,820	186,385	230,380
Selling, general and administrative	115,183	100,509	95,025	83,549	73,544	69,042	63,986	61,027	54,814	50,285
Operating income	136,116	126,055	105,202	93,058	81,560	64,276	49,478	47,373	40,900	85,720
EBIT	136,116	126,055	105,202	93,058	81,560	64,276	49,478	47,373	40,900	85,720
EBITDA	163,135	149,679	128,760	116,513	101,536	83,451	68,567	64,602	55,679	98,130
Interest expense	3,389	2,314	2,385	1,720	1,274	1,414	3,027	5,506	4,910	3,560
Pre-tax income	150,630	137,368	110,495	93,605	44,648	27,870	49,948	38,087	34,535	90,578
Income tax	35,544	27,720	14,395	8,476	10,755	5,147	8,228	6,009	9,110	12,116
Net income	114,794	109,290	95,764	84,736	32,727	29,038	37,649	26,654	20,957	69,644
Net income to common shareholders	114,794	109,290	95,764	84,736	32,727	29,038	37,649	26,654	20,957	69,644
Basic EPS	47.84	45.55	39.91	35.32	13.64	12.10	15.69	11.11	8.73	28.98
Diluted EPS	47.80	45.55	39.90	35.30	13.60	12.10	15.69	11.10	8.70	28.98
Average shares (basic)	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,403
Average shares (diluted)	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,399	2,404
Dividend per share	16.00	16.00	13.50	11.50	10.00	7.50	4.00	2.75	2.00	3.50